NeuroPace Inc (NPCE) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US6412881053

Price
12.69 USD
Market cap
435.58 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

NeuroPace Inc financials

Fiscal year2025
Revenue99.99 m USD
Gross profit77.22 m USD
Operating income-16.34 m USD
EBIT-16.82 m USD
Net income-21.47 m USD
Diluted EPS – continuing operations-0.66 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About NeuroPace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.